Hyponatremia. Hypokalemia.
Cautions.
DIAMOX is a white to faintly yellowish white crystalline, odorless powder, weakly acidic, very slightly soluble in water, and slightly soluble in alcohol.
Clinical trials of ivermectin did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients. Check with your physician if you have any of the following: Conditions: infection by the worm Loa Loa
These medications are not usually taken together.
Hyperchloremic acidosis.
Consult your healthcare professional (e.g., doctor or pharmacist) for more in formation.These medications may interact and cause very harmful effects. informational and educational purposes only. Consult your healthcare professional (e.g., doctor or pharmacist) for more in formation.These medications may cause some risk when taken together.
Ivermectin is derived from the avermectins, a class of highly active broad-spectrum, anti-parasitic agents isolated from the fermentation products of Streptomyces avermitilis.
2002
200 mcg/kg PO once; may require 1-2 additional doses repeated after 7 days 200 mcg/kg PO once as a single dose, THEN repeat dose once in 7 days Immunocompromised patients: 200 mcg/kg as single dose; may repeat in 14 days if necessaryStrongyloidiasis: The patient should be reminded of the need for repeated stool examinations to document clearance of infection with Onchocerciasis: The patient should be reminded that treatment does not kill the adult Onchocerca volvulus parasite, and therefore repeated follow-up and retreatment is usually requiredLong-term studies in animals have not been performed to evaluate carcinogenic potential of ivermectinTherapy had no adverse effects on fertility in rats in studies at repeated doses of up to 3 times maximum recommended human dose of 200 mcg/kg (on a mg/mImmunocompromised patients may require repeated treatment; control of extraintestinal strongyloidiasis may require suppressive therapy (eg, once monthly)There are no studies in pregnant women; epidemiologic studies during pregnancy are insufficient to inform a drug-associated risk of adverse developmental outcomes, because either the timing of administration during gestation was not accurately ascertained or the administration occurred only during the second trimester; however, systemic exposure from topical use of ivermectin is much lower than that from oral useIn animal reproduction studies, ivermectin induced adverse developmental outcomes when orally administered to pregnant mice, rats and rabbits during the period of organogenesis only at or near doses that were maternally toxic to the pregnant femalesThere is information available on the presence of ivermectin in human milk in 4 lactating women after a single 150 mcg/kg oral dose of ivermectin; however, there is insufficient information from this study to determine effects of ivermectin on breastfed infant or on milk productionTopical ivermectin systemic exposure is much lower than that for oral ivermectin; furthermore, amount of ivermectin present in human milk after topical application to lactating women has not been studiedThe developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for therapy and any potential adverse effects on breastfed infant or from underlying maternal conditionLactation: Enters breast milk (AAP Committee states compatible with nursing)A: Generally acceptable. Contraindications.
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.